Phase II Study of VELCADE for Relapsed or Refractory T-cell Prolymphocytic Leukemia
Withdrawn before enrolling · Phase 2
Conditions studied: Leukemia, Acute Lymphocytic Leukemia
In brief
We hope to learn more about the clinical efficacy of bortezomib in T-cell prolymphocytic leukemia. Patients will be selected as a possible participant in this study because they have a bone marrow disorder known as T-cell prolymphocytic leukemia (T-cell PLL) which does not tend to respond well to conventional treatment with chemotherapy.
Key facts
- Study ID
- NCT01162031
- Run by
- Stanford University
- People needed
- 0
- Starts
- 2010-06-01
- Expected to finish
- 2011-07-01
- Last updated by the study team
- 2018-05-21
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Stanford University School of Medicine — Stanford, California, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.